Anti-NGF mAb

NGF continues to draw considerable attention from the neuroscience research community, both in basic research as a prototypical neurotrophic factor and as a potential therapeutic agent for treatment of neurodegenerative diseases. To facilitate further research on NGF signaling, developmental regulation, and expression, Promega has developed an Anti-NGF mAb (Cat.# G1131, G1132).

PDF article (60kb)

Neural Notes Home